Verona Pharma plc: PDMR Dealing – Purchase by Chairman

LONDON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Dr. David Ebsworth, Chairman of the Company, has notified the Company that he has purchased a further 75,000 ordinary shares of 5 pence each in the Company (“Ordinary Shares”) at a total purchase price of £32,500, at prices between 42 and 45 pence per Ordinary Share and an average price of 43.33 pence.

Following the purchases, Dr. Ebsworth will have an interest in the Company of 370,387 Ordinary Shares, representing 0.35% of the Company’s issued share capital.

Further information is provided below in accordance with the requirements of the EU Market Abuse Regulation.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name David Ebsworth
2 Reason for the notification


b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Verona Pharma plc
b) LEI




4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 5 pence each    
  Identification code GB00BYW2KH80    
b) Nature of the transaction David Ebsworth purchased 75,000 Ordinary Shares    
c) Price(s) and volume(s) Date Price(s) Volume(s)
    11 November 2019 42 pence 25,000
    12 November 2019 43 pence 25,000
    13 November 2019 45 pence 25,000
d) Aggregated information 75,000 Ordinary Shares    
  -  Aggregated volume 43.33 pence    
  -  Price      
e) Dates of the transactions As per 4c) above    
f) Place of the transactions London Stock Exchange, AIM    

For further information, please contact:

Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer
Victoria Stewart, Director of Communications  
N+1 Singer
(Nominated Adviser and UK Broker)
Tel: +44 (0)20 3283 4200
Aubrey Powell / George Tzimas (Corporate Finance)  
Mia Gardner (Corporate Broking)